Work

In-vivo-targeted gene delivery using adenovirus-antibody site-specific covalent conjugates

Year: 2025

Type: article

Abstract: performance is currently suboptimal and additional engineering is needed prior to further use, these studies form the basis of a novel method for targeting adenovirus that can be combined with additional well-characterized adenovirus modifications toward applications in cell engineering, gene therapy, vaccines, oncolytics, and others.

Source: Molecular Therapy — Methods & Clinical Development

DOI: 10.1016/j.omtm.2025.101497

Authors: Paul J. Rice-Boucher, Elena A. Kashentseva, Igor P. Dmitriev, Hongjie Guo, Jacqueline M. Tremblay, Charles B. Shoemaker, David T. Curiel, Zhi Hong Lu

Institutions: Washington University in St. Louis, Tufts University

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering

Awards: G2681561777, A Novel Vector Platform to Actualize T Cell Modification In Vivo, G4847001145, G7421941214, Pre-and Postgraduate Training in Molecular Hematology

OpenAlex ID: W4410759335

FWCI: 2.665

Cites: 67

Cited by: 5

Related to: 10